Amy Horton sells 12,430 shares of Artivion, Inc. (NYSE:AORT)

Artivion, Inc. (NYSE:AORT – Get Your Free Report ) CAO Amy Horton sold 12,430 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the transaction, the chief accounting officer now directly owns 139,989 shares of the company’s stock, valued at approximately $3,664,912.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available on the SEC’s website.

Artition Stock 0.2%

Shares of AORT traded up $0.06 during mid-day trading on Wednesday, reaching $26.33. The company’s stock had a trading volume of 173,589 shares, compared to its average volume of 226,079. The company’s 50-day moving average is $25.79 and its 200-day moving average is $24.01. The company has a current ratio of 5.63, a quick ratio of 4.04, and a debt-to-equity ratio of 1.07. Artivion, Inc. has a 12-month low of $12.16 and a 12-month high of $29.24. The company has a market cap of $1.10 billion, a PE ratio of -109.46 and a beta of 1.74.

Artivion (NYSE:AORT – Get Free Report ) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.04. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. The firm had revenue of $98.02 million for the quarter, compared to the consensus estimate of $97.70 million. On average, equities research analysts forecast that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.

Analysts on Wall Street are forecasting an increase

A number of research analysts recently issued reports on the stock. Oppenheimer raised their target price on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Artivion in a report on Friday, September 27th. Stifel Nicolaus lifted their price objective on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, Lake Street Capital boosted their price target on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd.

Check out our latest research report on Artivion

Institutional inputs and outputs

Several hedge funds have recently made changes to their positions in the stock. First Eagle Investment Management LLC grew its position in shares of Artivion by 8.1% in the first quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock valued at $12,066,000 after buying an additional 42,705 shares during the last quarter. Wasatch Advisors LP grew its position in Artivion by 108.8% in the first quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock worth $22,928,000 after acquiring an additional 564,549 shares during the period. Vanguard Group Inc. raised its stake in shares of Artivion by 1.3% in the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after purchasing an additional 33,982 shares during the last quarter. Tidal Investments LLC purchased a new position in shares of Artivion in the first quarter worth $257,000. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Artivion by 291.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock valued at $118,000 after acquiring an additional 4,154 shares during the period. 86.37% of the shares are held by hedge funds and other institutional investors.

About Artivion

(Get a free report)

Artivion, Inc manufactures, processes and distributes medical devices and implantable human tissues worldwide. The company supplies BioGlue, a polymer made of bovine blood proteins and a protein cross-linking agent for cardiac, vascular, neurological and pulmonary procedures; Heart preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open Plus and E-vita Open Neo.

Recommended articles

Get news and reviews for Artivion Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Artivion and related companies with MarketBeat.com’s FREE daily email newsletter.